within Pharmacolibrary.Drugs.ATC.L;

model L04AG04
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 2.8333333333333335e-06,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0037,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0025499999999999997,
    k12             = 0.228,
    k21             = 0.228
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Belimumab is a fully human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS or BAFF) and is approved for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in adults and pediatric patients. It is administered as an adjunct to standard therapy and reduces disease activity by limiting the survival and differentiation of B cells.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with SLE following intravenous administration. Mixed sex, adult patients, typical body weight 76 kg.</p><h4>References</h4><ol><li><p>Brunner, HI, et al., &amp; Ruperto, N (2020). Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. <i>Annals of the rheumatic diseases</i> 79(10) 1340–1348. DOI:<a href=&quot;https://doi.org/10.1136/annrheumdis-2020-217101&quot;>10.1136/annrheumdis-2020-217101</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32699034/&quot;>https://pubmed.ncbi.nlm.nih.gov/32699034</a></p></li><li><p>Meng, X, et al., &amp; Lu, H (2021). Pharmacokinetics and Safety of Intravenous and Subcutaneous Auto-injector Single-dose Belimumab in Healthy Chinese Volunteers: A phase 1, Randomized, Open-label Study. <i>Rheumatology and therapy</i> 8(4) 1711–1724. DOI:<a href=&quot;https://doi.org/10.1007/s40744-021-00366-0&quot;>10.1007/s40744-021-00366-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34554352/&quot;>https://pubmed.ncbi.nlm.nih.gov/34554352</a></p></li><li><p>Dimelow, R, et al., &amp; Struemper, H (2021). Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus. <i>Clinical pharmacology in drug development</i> 10(6) 622–633. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.889&quot;>10.1002/cpdd.889</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33245847/&quot;>https://pubmed.ncbi.nlm.nih.gov/33245847</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG04;
